A friendly A$500 million (US$345 million) merger that promised to create Australia’s largest pure biotech company has been called off after hitting a major obstacle over one partner’s dispute with a U.S. company.
A friendly A$500 million (US$345 million) merger that promised to create Australia’s largest pure biotech company has been called off after hitting a major obstacle over one partner’s dispute with a U.S. company.
